Loading
Life sciences · Journal article
Expert Opinion on Pharmacotherapy · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Medullary thyroid cancer (MTC) is a less common subtype of thyroid cancer, and it should be managed under the care of expert multidisciplinary teams.Areas covered Based on the available literature, the role of systemic therapy for MTC has evolved over the past couple of decades in line with the rapid development in our understanding of the biology of this cancer. Despite the initial successes of selective RET inhibitors in achieving good responses and reasonable disease control, resistance eventually develops in most patients.Expert opinion There is an unmet need to develop newer therapeutic approaches for the management of MTC. This should happen through multicenter, international collaborative efforts given the rarity of this cancer.